DOI: https://doi.org/10.22141/2224-1485.3.35.2014.82727

Do We Need Arguments Concerning What is Better, Sartans or ACE Inhibitors? (Part 2)

A.D. Radchenko

Abstract


This paper is a review of the literature data on the impact of angiotensin II receptor blockers on the incidence of cardiovascular events. We compared their efficacy in the prevention of complications with angiotensin-converting enzyme inhibitors. The comparison of tolerability and safety of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors use is being carried out. Conclusions were made that there is no significant difference, that would have clinical significance, between angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.

Keywords


angiotensin-converting enzyme inhibitors; sartans; efficiency; safety

References


Радченко А.Д. Нужны ли споры на тему: лучше сартаны или ингибиторы АПФ? (часть 1) // Артериальная гипертензия. — 2014. — № 2. — С. 97-111.

2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — Vol. 31. — P. 1281-1357.

Akishita M., Horiuchi M., Yamada H. et al. Inflammation influences vascular remodeling through AT2 expression and signaling // Physiol. Genom. — 2000. — Vol. 2. — P. 13-20

ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin—converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288. — P. 2981-2997.

Azoulay L., Assimes T.L., Yin H., Bartels D.B., Schiffrin E.L., Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer // PLoS One. — 2012. — Vol. 7 (12). — P.: e50893. doi: 10.1371/journal.pone.0050893. Epub 2012 Dec 12.

Bangalore S., Kumar S., Wetterslev J., Messerli F. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials // BMJ. — 2011. — Vol. 342. — P. 22-34

Blood Pressure Lowering Treatment Trialist’ Collabaration. Blood pressure-dependent and independent effects of agents that inhibit the rennin-angiotensin system // J. Hypertens. — 2007. —

Vol. 25. — P. 951-958.

Bourgault C., Senecal M, Brisson M. et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study // J. Hum. Hypertens. — 2005. — Vol. 19 (8). — P. 607-613.

Braunwald E., Domanski M.J., Fowler S.E. et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease // N. Engl. J. Med. — 2004. — Vol. 351. — P. 2058-2068.

Brenner B., Cooper M., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. — 2001. — Vol. 345. — P. 861-869

Brown N.J., Byiers S., Carr D. et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema // Hypertension. — 2009. — Vol. 54. — P. 516-523.

Cheung B., Cheung G., Lauder I. et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension // J. Hum. Hypertens. — 2006. —Vol. 20. — P. 37-43.

Connolly S. et al. Effects of telmisartan, irbesartan, valsartan, candesartan and losartan on cancer in 15 trials enrolling 138769 individuals. The ARB Trialist Collaboration // J. Hypertens. — 2011. — Vol. 29 (4). — P. 623-635.

Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Dalby A., McMurray J. VALIANT trial results support use of valsartan in acute myocardial infarction // Cardiovasc. Journal of South Africa. — 2003. — e-publication 5 December 2 — P. 1-3 (www.cvjsa.co.za).

Delea T., Taneja C, Moynahan A. et al. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension // American Journal of Health-System Pharmacy. — 2007. — Vol. 64. — P. 1187-1196.

Doane J., Barry Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review". ACCF / AHA 2011 Expert Consensus Document on Hypertension in the Elderly // J. Clin. Hypertens. — 2013. — Vol. 15. — P. 230-233.

Dykewicz M. Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into Mechanisms and Management // http://www.medscape.com/viewarticle/484537_2.

Elliott W., Basu S., Meyer P. Initial drugs for coronary heart disease prevention in hypertensive patients: network and Bayesian meta-analysis of clinical trial data // J. Clin. Hypertension. — 2009. — Vol. 11. — P. A7.

Elliott W., Plauschinat C., Skrepnek G., Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies // L. Am Board Fam. Med. — 2007. — Vol. 20. — P. 72-80.

Elliott W.J. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects // Clin. Pharmacol. Ther. — 1996. — Vol. 60. — P. 582-588.

Fegan G., Ward D., Clarke L. et al. The HOPE study and diabetes: Heart Outcomes Prevention Evaluation // Lancet. — 2000. — Vol. 355. — P. 1182-1183.

Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion // Vascular Health and Risk Management. — 2009. — Vol. 5. — P. 21-29.

Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study) // Lancet. — 2003. — Vol. 362. — P. 782-788.

Gibbons R.J., Abrams J., Chatterjee K. et al. Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease [in Spanish] // Rev. Esp. Cardiol. — 2004. — Vol. 57. — 1213-1232.

Glander P., Diekmann F., Dragun D., Neumayer H.H., Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. // Clin. J. Am. So.c Nephrol. — 2010. — Vol. 5 (4). — P. 703-708.

Granger B.B., Swedberg K., Ekman I. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial // Lancet. — 2005 — Vol. 366. — P. 2011.

Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial // Lancet. — 2003. — Vol. 362. — P. 772-776.

Hansson L. Why don’t you do as I tell you? Compliance and antihypertensive regimens // Int. J. Clin. Pract. — 2002. — Vol. 56 (3). — P. 191-196.

http//www.medscape.com/viewarticle/507293

http://www.fda.gov/Drugs/DrugSafety/ucm354856.htm

Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363. — P. 2022-2031.

Kaiser Permanente Care Management Institute. Guildelines: Secondary prevention of coronary artery disease clinical practice guidelines. — Oakland (CA): Kaiser Permanente Care Management Institute, 2006. — 117 p.

Kasanuki H., Hagiwara N., Hosoda S. et al. Angiotensin II receptor blocker-based vs. Non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) // Eur. Heart J. — 2009. — Vol. 30. — P. 1203-1212.

Ker J., Rheeder P. The effect of angiotensin receptor blockers on myocardial infarction: what are we to believe? // Cardiovascular Journal of South Africa. — 2005. — Vol. 16, № 2. — P. 81.

Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. — 2009. — Vol. 338. — P. 1665.

Lee V., Rhew D., Dylan M. et al. Meta-analysis: angiotensin A receptor blockers in chronic heart failure and high risk acute myocardial infarction // Ann. Intern Med. — 2004. — Vol. 141. — P. 693-704.

Lindholm L.H., Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 1004-1010.

Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double—blind intervention trial // J. Hypertens. — 2003. —

Vol. 21. — P. 875-886.

Matchar D.B., McCrory D.C., Orlando L.A. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension // Ann. Intern. Med. — 2008. — Vol. 148. — P. 16-29.

Mazzaglia G., Mantovani L., Sturkenboom M. et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care // J. Hypertens. — 2005. — Vol. 23 (11). — P. 2093-2100.

McDonald M., Simpson S., Ezekowitz J. et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review // BMJ. — 2005. — Vol. 331. — P. 873-879.

McKelvie R.S., Yusuf S., Pericak D. et al. the RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study // Circulation. — 1999. — Vol. 100. — P. 1056-1064.

McMurray J. Letter. Angiotensin receptor blockers and myocardial infarction. Analysis of evidence is incomplete and inaccurate // BMJ. — 2005. — Vol. 330. — P. 1269.

McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial // Lancet. — 2003. — Vol. 362. — P. 767-771.

Messerli F.H., Bangalore S., Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? // Eur. Heart J. — 2009. — Vol. 30 (20). — P. 2427-30.

MICRO-HOPE Study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE substudy // Lancet. — 2000. — Vol. 355. — P. 253-259.

Møller J., Dahlström U., Gøtzsche O. et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy // Am. Heart J. — 2004. — Vol. 147. — P. 494-501.

Opie L. ARBs and mortality in myocardial Infarction // Cardiovascular Journal of South Africa. — 2005. — Vol. 16, № 2. — P. 84.

Parving H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345. — P. 870-878.

Pfeffer M.A., Swedberg K., Granger C.B. Et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme // Lancet. — 2003. —

Vol. 362. — P. 759-766.

Pitt B, Poole-Wilson PA, Segal R. et al.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II // Lancet. — 2000. — Vol. 355. — P. 1582-1587.

Pitt B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) // Lancet. — 1997. — Vol. 349. — P. 747-752.

Rayner B. Comments. Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients // Cardiovascular Journal of South Africa. — 2008, advance publication 10 September. — P. 1.

Reboldi G., Angeli F., Cavallini C. et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis // J. Hypertens. — 2008. — Vol. 26 (7). — P. 1282-1289.

Schrader J., Luders S., Kulschewski A. et al. Morbidity and Mortality аfter Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES) // Stroke. — 2005. — Vol. 36. — P. 1218-1226.

Siiskonen S., Breekveldt-Postma N., Vincze G. Higher persistence with valsartan compared with enalapril in daily practice // Vasc. Health Risk Manag. — 2007. — Vol. 3 (6). — P. 1039-1044.

Sipahi I., Debanne S., Rowland D., Simon D. et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials // The Lancet Oncology. — 2010. — Vol. 11. —

P. 627-636.

Strauss M., Hall A. Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox // Circulation. — 2006. — Vol. 114. — P. 838-854.

Strauss M., Lonn E., Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta—analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration // European Heart Journal. — 2005. — Vol. 26. — P. 2351-2353.

Strippoli G.F., Craig M., Deeks J.J., Schena F.P., Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review // BMJ. — 2004. — Vol. 9, № 329. — P. 828.

The ONTARGET Investigators Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events // N. Engl. J. Med. — 2008. — Vol. 358. — P. 1547-1559.

The Task force for management of stable angina pectoris of European Society of cardiology: full text // Eur. Heart J. — doi: 10.1093 / eurheartj / ehl002.

The Task Force for the Management of Arterial Hypertension of the ESH and ESC 2007 // J. Hypertens. — 2007. — Vol. 25. — P. 1105-1187.

The Task force members. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 // Eur. Heart J. — 2008. — Vol. 29. — P. 2388-2442.

The Task force members. European guidelines on cardiovascular disease prevention in clinical practice: executive summary // Eur. Heart J. — 2007. — Vol. 28. — P. 2375-2414.

The Task force members. European guidelines. Management of acute myocardial infarction in patients with presenting persistent ST-segment elevation // Eur. Heart J. — 2008. — Vol. 29. — P. 2909-2945.

The Task force members. Guidelines in diabetes, prediabetes and cardiovascular disease: full text // Eur. Heart J. — doi: 10.1093/eurheartj/eht108

The Task Force on the management of ST—segment elevation acute myocardial infarction of the European Society of Cardiology (ESCESC Guildelines for the mangement of acute myocardial infarction in patients presenting with ST-segment elevation // Eur. Heart J. — 2012. — Vol. 33.— P. 2569-2619.

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // The Lancet. — 2008. — Vol. 372. — P. 1174-1183.

Tsuyuki R., McDonald M. Angiotensin Receptor Blockers Do Not Increase Risk of myocardial Infarction // Circulation. — 2006. — Vol. 114. — P. 855-860.

vanVark L.C., Bertrand M., Akkerhuis K.M. еt al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart J. — 2012. — Vol. 33 (16). — P. 2088-2097.

Vegter S., Nguyen N., Visser S. et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs // Am. J. Manag. Care. — 2011. — Vol. 17 (9). — P. 609-616.

Verdecchia P., Angeli F., Gattobigio R., Reboldi G.P. Do angiotensin II receptor blockers increase the risk of myocardial infarction? // Eur. Heart J. — 2005. — Vol. 26. — P. 2381-2386.

Verdecchia P., Reboldi G., Angeli F. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. — 2005. —

Vol. 46. — P. 386-392.

Verma S., Mamdani M., Al-Omran M. et al. Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results) // J. Am. Soc. Hypertens. — 2007. — Vol. 1. — P. 286-294.

Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction // BMJ. — 2004. — Vol. 329. — P. 1248-1249.

Visser L.E., Stricker B.H., van der Velden J. et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study // J. Clin. Epidemiol. — 1995. — Vol. 48. — P. 851-857.

Volpe M., Mancia G., Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds // J. Hypertens. — 2005. — Vol. 23. — P. 2113-2118.

Volpe M., Tocci G., Sciarretta et al. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials // J. Hypertens. — 2009. — Vol. 27. — P. 941-946.

Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial // Lancet. — 2004. — Vol. 363. — P. 2049-2051.

Yiannakopoulou E.Ch1., Papadopulos J.S., Cokkinos D.V., Mountokalakis T.D. Adherence to antihypertensive treatment: a critical factor for blood pressure control // Eur. J. Cardiovasc. Prev. Rehabil. — 2005. — Vol. 12 (3). — P. 243-249.

Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial // Lancet. — 2003. — Vol. 362. — P. 777-781.

Yusuf S., Sleight P., Pogue J. et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // N. Engl. J. Med. — 2000.




Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта